Turn Therapeutics Inc. — Form 8-K

Turn Therapeutics completed a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis (AD). The trial enrolled ~50 patients in Stage 1. Interim data showed clinically meaningful efficacy across a broader disease-severity spectrum than originally anticipated, including patients with mild-to-moderate AD (baseline EASI 1.1–7.0). The optimized Stage 2 design will now prospectively enroll ~120–135 patients stratified across the full EASI spectrum (1.1–7.0, 7.1–15.9, ≥16), evaluate four prespecified endpoints using FDA-recognized Hochberg multiple-testing procedure, and complete enrollment by Q4 2026. No serious adverse events or discontinuations have been reported; safety profile remains favorable. The company states it remains sufficiently capitalized through Q3 2027.